Cell therapy can now regrow lost cartilage in selected young knees and help save hips with early avascular necrosis. It is not a cure-all, and it works best when the right patient gets it at the right stage.
Picture an athlete in the 1980s who tears his knee ligament, meniscus and cartilage in one bad moment. Surgeons could rebuild the ligament and cut out the meniscus, but nothing could be done for the damaged cartilage. By fifty, he had arthritis.
The same athlete today has keyhole surgery: the ligament is reconstructed, the meniscus repaired, and the cartilage restored. Some of that restoration is now done with the patient's own cells, grown in a laboratory. This article explains how that works, who it suits, and what the research actually shows.
What are stem cells?
Stem cells are the body's root cells. They can divide into daughter cells and turn into specialised tissue such as bone or cartilage. Adults keep a small reserve of them, mainly in the bone marrow.
The body rarely has the right conditions to multiply these cells enough to rebuild a damaged joint surface. In a laboratory, though, a few of your own cells can be grown into millions, steered towards one job, and then returned to you.
A note on terms. "Stem cell therapy" is often used loosely. In orthopaedics it covers two related treatments: concentrated or cultured bone marrow cells (which include true mesenchymal stem cells), and cultured cartilage cells (chondrocytes) or bone-forming cells (osteoblasts) grown from your own tissue. All use your own cells, so there is no rejection risk.
Which conditions can it help?
Cell therapy is used to regrow two tissues: cartilage and bone.
|
Condition |
What cell therapy aims to do |
Best suited to |
|---|---|---|
|
Cartilage loss in the knee, ankle or hip (contained defects) |
Fill the defect with new cartilage-like tissue |
Younger, active people with a focal defect and little or no arthritis |
|
Avascular necrosis (AVN) of the hip |
Help dead bone in the femoral head repair before it collapses |
Early-stage AVN, before the ball of the hip has collapsed |
It is not a treatment for widespread, "bone-on-bone" osteoarthritis. In that situation a joint replacement usually remains the reliable option.
How does stem cell therapy work?
Treatment usually takes two procedures, about 4 to 6 weeks apart.
- Harvest. Your own cells are collected in one of two ways:
- a small piece of cartilage, with the bone beneath it, taken by arthroscopy (keyhole surgery) from a non-weight-bearing part of the knee, or
- bone marrow drawn with a needle from the back of the pelvic bone.
- Laboratory growth. The sample is labelled and sent to a certified cell laboratory. The cells are separated and stimulated to grow one specialised cell line, multiplying into millions. This takes around 4 to 6 weeks.
- Implantation. The cells return to the hospital. In a second procedure they are placed into the cartilage defect, or into the damaged bone, where they help regenerate tissue.
For AVN of the hip, cells are commonly delivered through a core decompression: a narrow channel drilled into the dead area of the femoral head, which relieves pressure and gives the cells a path in.
What does the evidence say?
The evidence is strongest for cultured cartilage cells in the knee, and encouraging but more mixed for hip AVN.
Cartilage repair
- Randomised trial evidence. The SUMMIT trial randomised 144 patients with knee cartilage defects of 3 cm² or larger to cultured cartilage cells on a collagen membrane (MACI) or to microfracture. At 5 years, the cell-therapy group still had significantly better pain and function scores. MRI defect fill was similar in both groups (Brittberg et al., 2018).
- Long-term durability. A 2024 Mayo Clinic review pooled 168 patients followed for at least 10 years after MACI. Improvements held, 9.0% needed further surgery, and 7.4% went on to knee replacement at 10 to 17 years (Wang et al., 2024). These studies were case series, so this is lower-level evidence.
- Guideline view. The UK's NICE recommends cultured cartilage cell implantation for knee defects over 2 cm², in people with minimal arthritis and no previous cartilage repair surgery, done at a specialist centre (NICE TA477).
- Indian data. A phase III study at four Indian centres treated 14 young adults with a locally approved cultured cartilage product. Knee function scores (IKDC) roughly doubled, from 33 to 60, at 4 years, with no reported side effects (Pathak et al., 2022). The study was small and had no control group.
Avascular necrosis of the hip
- Long-term French data. In 125 patients with early AVN in both hips, one hip received bone marrow cells and the other core decompression alone. At an average of 25 years, 24% of the cell-treated hips needed replacement versus 76% of the decompression-only hips (Hernigou et al., 2018).
- A cautionary trial. A double-blind randomised trial added cultured bone-forming cells to core decompression in early AVN and found no added benefit at 2 years (Clin Orthop Relat Res, 2023).
- What predicts success. A 908-hip analysis found partial bone repair was common and complete repair rare. Smaller lesions, earlier stage and a higher number of cells gave better results (Hernigou et al., 2024).
Bottom line: for the right cartilage defect, cell therapy has trial-backed, durable results. For hip AVN, it is a reasonable joint-preserving option before collapse, but results vary and you should expect improvement rather than a guaranteed cure.
Can embryonic stem cells from a family member be used instead?
Not at present. Embryonic stem cells are not used for orthopaedic stem cell therapy, for three reasons:
- Uncontrolled growth. Embryonic cells can grow irregularly. Steering them into a single, specialised cell line is still an unsolved research problem, and stray undifferentiated cells carry a risk of tumours called teratomas (Hong & Lee, review).
- Rejection. Cells from another person, even a relative, can trigger an immune response. Preventing it means long-term immunosuppressant drugs, which themselves raise the risk of infection and cancer.
- No proof it lasts. The cells may simply stop working in the recipient over time, and there is no clinical validation for joint repair.
Your own adult cells avoid all three problems, which is why they are the standard today.
What can I expect after treatment?
Most people return to sport 4 to 6 months after implantation.
|
Time after implantation |
What happens |
|---|---|
|
Weeks 0–3 |
The area is protected from full weight-bearing. Gentle passive movements keep the joint mobile. |
|
By week 6 |
The new tissue starts to stabilise; rehabilitation builds up. |
|
Months 4–6 |
Most people return to sporting activities. |
Your exact protocol depends on the joint, the size and site of the defect, and any other surgery done at the same time. Your surgeon and physiotherapist will tailor it to you.
Is it right for me?
You may be a good candidate if:
- you have a well-defined (contained) cartilage defect, confirmed on MRI or arthroscopy
- the rest of the joint has little or no arthritis
- you have early-stage hip AVN, before the femoral head has collapsed
- problems such as ligament instability or poor leg alignment are corrected first or at the same time
- you can commit to several months of structured rehabilitation
How to spot an unproven "stem cell" clinic
In India, cultured cartilage and bone cell products have been licensed by the Drugs Controller General of India after clinical trials (Business Standard). Outside approved uses, ICMR's national guidelines say any stem cell use in patients must happen only within an approved clinical trial (Nature India). In 2026 the National Medical Commission reinforced this after a Supreme Court ruling (Medical Dialogues).
Be wary of any provider who:
- promises to "cure" advanced arthritis or avoid a joint replacement for everyone
- offers a single injection for many unrelated conditions
- cannot name the licensed product or the approved trial being used
- asks for large upfront payments for an "experimental" treatment
Looking ahead
We can grow bone cells and cartilage cells, but we cannot yet grow a whole joint. A joint is many tissues built in layers. The thin "tidemark" that bonds cartilage to bone, for example, has not yet been recreated in the lab.
Building living tissue needs three things: a scaffold for cells to sit on, the right signals telling cells what to become, and the right timing. Progress is coming. At Italy's Rizzoli Institute, surgeons developed a three-layer scaffold, bone below and cartilage above. In a 100-patient randomised trial it matched microfracture overall and did better in deep osteochondral lesions and sports-active patients (Kon et al., 2017).
Every step forward will have to earn its evidence, and that is how it should be.
Frequently asked questions
Is stem cell therapy for knee cartilage approved in India?
Yes, for specific licensed products. Cultured cartilage and bone cell products made from your own cells have been approved by the Drugs Controller General of India after clinical trials. Other stem cell uses are allowed only within approved clinical trials.
Can stem cell therapy help me avoid a knee replacement?
It can for the right patient. It works for well-defined cartilage defects in joints with little arthritis. It is not a substitute for a replacement in advanced, bone-on-bone osteoarthritis.
How long does stem cell therapy take?
It involves two procedures about 4 to 6 weeks apart. The first collects your cells; the laboratory then grows them; the second implants them.
How long is recovery after stem cell therapy?
The joint is protected from full weight-bearing for the first few weeks. The new tissue starts to stabilise by about 6 weeks, and most people return to sport at 4 to 6 months.
Is stem cell therapy safe?
Because the cells are your own, there is no risk of rejection and no need for immune-suppressing drugs. The main risks are those of the two procedures themselves, which your surgeon will discuss with you.
Does stem cell therapy work for avascular necrosis of the hip?
It works best in early AVN, before the femoral head collapses. Long-term studies show fewer hip replacements after cell therapy, though results vary with the size and stage of the lesion.
Speak to a specialist
If you have a cartilage injury or early hip AVN, a consultation can tell you whether cell therapy, another joint-preserving procedure or a different approach suits you best. This article is for general information and does not replace individual medical advice.
References
- Brittberg M, et al. Matrix-applied characterized autologous cultured chondrocytes versus microfracture: five-year follow-up of a prospective randomized trial. Am J Sports Med. 2018;46(6):1343–1351. PubMed
- Wang AS, et al. Minimum 10-year outcomes of matrix-induced autologous chondrocyte implantation in the knee: a systematic review. Am J Sports Med. 2024;52(9):2407–2414. PubMed
- NICE. Autologous chondrocyte implantation for treating symptomatic articular cartilage defects of the knee (TA477). 2017. nice.org.uk
- Pathak S, et al. Efficacy and safety of CARTIGROW in patients with articular cartilage defects of the knee joint: a four year prospective study. Int Orthop. 2022;46:1313–1321. Springer
- Hernigou P, et al. Cell therapy versus simultaneous contralateral decompression in symptomatic corticosteroid osteonecrosis: a thirty year follow-up prospective randomized study of 125 adult patients. Int Orthop. 2018. Springer Medicine
- Does adjunction of autologous osteoblastic cells improve the results of core decompression in early-stage femoral head osteonecrosis? A double-blind, randomized trial. Clin Orthop Relat Res. 2023. PMC
- Hernigou P, et al. Mesenchymal stem cell therapy for bone repair of human hip osteonecrosis with bilateral match-control evaluation: 908 hips. Cells. 2024. DOAJ
- Challenges to the clinical application of pluripotent stem cells: genomic and functional stability, teratoma risk and immunogenicity (review). PMC
- Kon E, et al. A multilayer biomaterial for osteochondral regeneration shows superiority vs microfractures for the treatment of osteochondral lesions in a multicentre randomized trial at 2 years. Knee Surg Sports Traumatol Arthrosc. 2017. PMC
- ICMR–DBT National Guidelines for Stem Cell Research, 2017 (summary). Nature India
- NMC advisory on stem cell therapy following the Supreme Court judgment, 2026. Medical Dialogues